Suggested remit: To appraise the benefits and costs of tofersen within its marketing authorisation for treating amyotrophic lateral sclerosis for national commissioning by NHS England.
The National Institute for Health and Care Excellence (NICE) has been asked to conduct an evaluation of tofersen for treating amyotrophic lateral sclerosis caused by SOD1 gene mutations ID3967. We recently incorrectly invited stakeholders to respond to a written consultation on the draft scope and to attend a scoping workshop for this appraisal. To confirm NICE will not be progressing with the scoping exercise at this time. The consultation on the draft scope will now close and the workshop arranged for Friday 17 December 2021 has been cancelled. Please accept our apologies for any inconvenience.
 
Status Suspended
Process HST
ID number 3767

Project Team

Project lead Michelle Adhemar

Email enquiries

Timeline

Key events during the development of the guidance:

Date Update
17 December 2021 (14:00) Scoping workshop
04 November 2021 - 02 December 2021 Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators
11 November 2021 Suspended. The National Institute for Health and Care Excellence (NICE) has been asked to conduct an evaluation of tofersen for treating amyotrophic lateral sclerosis caused by SOD1 gene mutations ID3967. We recently incorrectly invited stakeholders to respond to a written consultation on the draft scope and to attend a scoping workshop for this appraisal. To confirm NICE will not be progressing with the scoping exercise at this time. The consultation on the draft scope will now close and the workshop arranged for Friday 17 December 2021 has been cancelled. Please accept our apologies for any inconvenience.

For further information on how we develop guidance, please see our page about NICE highly specialised technologies guidance